Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 96

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 96
---
idence,                                                                                                                  
 prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management 
 and treatment, Critical Care. Hassoun et al, Aug 2017                                                                       |

<div align='center'>61

Our Second Lead Candidate, Nano-Candesartan (nanoparticles-based ARB), is being targeted for combination

therapy with an initial indication in pancreatic ductal adenocarcinoma (PDAC).</div>

Nano-Candesartan, our nanoparticles-based
formulation of an angiotensin receptor blocker (ARB), is being evaluated as a potential combination therapy candidate, with an initial
focus on pancreatic ductal adenocarcinoma (PDAC), an indication with a significant unmet medical need.

In 2023, we entered into an option agreement
with Yissum, the technology transfer company of the Hebrew University of Jerusalem, relating to a preclinical liposomal angiotensin receptor
blocker (Nano-Candesartan, or ARB) program. Under the terms of the agreement, following completion of four designated preclinical studies,
Yissum is required to deliver a final scientific report summarizing the results of those studies. Delivery of this final scientific report
is a condition precedent to the commencement of a 90-day option exercise period, plus an additional 120-day negotiation period, during
which we may negotiate an exclusive license to the ARB program.

As of the date of this prospectus, we do not
believe that Yissum has delivered a final scientific report that meets the definition set forth in the option agreement. Certain data,
analyses, and supporting materials that we understood would form part of the final scientific report remain outstanding. In addition,
research activities continued throughout 2024 and 2025 under the approved research plan, with the knowledge and involvement of Yissum
and University personnel, further supporting our understanding that the option period had not yet commenced.

In November 2025, Yissum informed us that,
in its view, the final scientific report had been delivered in September 2024 and that the option exercise period had therefore expired.
We dispute this position and have communicated to Yissum that the September 2024 report did not include the components specified under
the agreement and therefore does not constitute a final scientific report. We and Yissum are currently engaged in discussions to resolve
this matter, and there can be no assurance as to the timing, outcome, or potential impact of these discussions